Provention Bio, Inc.
PRVB · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $11 | $1 | $1 | $1 |
| % Growth | 1,330.3% | 1.3% | 28.6% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | $10 | $1 | $1 | $1 |
| % Margin | 95.3% | 100% | 100% | 100% |
| R&D Expenses | $26 | $16 | $17 | $17 |
| G&A Expenses | $24 | $13 | $14 | $12 |
| SG&A Expenses | $24 | $13 | $14 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Expenses | $50 | $30 | $31 | $30 |
| Operating Income | -$40 | -$29 | -$30 | -$29 |
| % Margin | -371.5% | -3,846.3% | -3,999.1% | -5,014% |
| Other Income/Exp. Net | $1 | $0 | $0 | $0 |
| Pre-Tax Income | -$40 | -$29 | -$30 | -$29 |
| Tax Expense | -$6 | -$0 | -$0 | -$7 |
| Net Income | -$33 | -$28 | -$30 | -$22 |
| % Margin | -307.7% | -3,728.6% | -3,959.9% | -3,787.6% |
| EPS | -0.45 | -0.34 | -0.46 | -0.35 |
| % Growth | -32.4% | 26.1% | -31.4% | – |
| EPS Diluted | -0.45 | -0.34 | -0.46 | -0.35 |
| Weighted Avg Shares Out | 75 | 83 | 65 | 63 |
| Weighted Avg Shares Out Dil | 75 | 83 | 65 | 63 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $1 | $0 | $0 |
| EBITDA | -$38 | -$28 | -$29 | -$29 |
| % Margin | -351.6% | -3,734.7% | -3,941.7% | -4,990.3% |